Revenue ($USD): $3,189,755,036
Revenue (foreign currencies): DKK kr22,579,000,000
R&D spend: $122,340,576.00
Employees: 13,650
Fiscal year end: 09/30/22
CEO: Kristian Villumsen
Coloplastannounced in June 2023that it entered into an agreement to acquire Kerecis, a developer of biologics for the wound care market. Coloplast sees Kerecis as an “attractive opportunity” to strengthen its presence in the advanced wound care market.–CN and SW